Beam Therapeutics BEAM Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $164.01M+17.4% | $139.74M+151% | $55.7M-7.6% | $60.27M-5.2% | $63.58M+0.1% | ||
| $415.33M+1.4% | $409.62M-0.5% | $411.79M+3.9% | $396.28M+3.9% | $381.56M+3.8% | ||
| $120.31M+5.7% | $113.82M+3.3% | $110.2M+0.2% | $109.97M-2.5% | $112.74M+1.1% | ||
| $535.63M+2.3% | $523.44M+0.3% | $521.99M+3.1% | $506.25M+2.4% | $494.3M+3.2% | ||
| -$371.62M+3.1% | -$383.69M+17.7% | -$466.29M-4.6% | -$445.98M-3.5% | -$430.72M-3.6% | ||
| -226.6%+48.0pp | -274.6%+563pp | -837.1%-97.2pp | -739.9%-62.5pp | -677.5%-23.2pp | ||
| $306.58M+0.6% | $304.64M+479% | $52.58M+8.8% | $48.34M+9.0% | $44.36M+14.1% | ||
| —— | —— | -$413.7M-4.0% | -$397.64M-2.9% | -$386.4M-2.6% | ||
| —— | —— | -$4.42+1.6% | -$4.49+2.4% | -$4.60-0.4% | ||
| -$349.25M+3.4% | -$361.4M+18.6% | -$444.22M-4.8% | -$423.99M-3.7% | -$408.7M-3.8% | ||
| -212.9%+45.7pp | -258.6%+539pp | -797.5%-94.0pp | -703.5%-60.6pp | -642.8%-23.1pp | ||
| -$371.62M+3.1% | -$383.69M+17.7% | -$466.29M-4.6% | -$445.98M-3.5% | -$430.72M-3.6% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Beam Therapeutics's income statement data come from?
- Every line is extracted from Beam Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.